These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10961248)

  • 1. Etiology and pathogenesis of rheumatic diseases of adolescence.
    Petty RE
    Adolesc Med; 1998 Feb; 9(1):11-24. PubMed ID: 10961248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genes and joints: a challenge for the future.
    Siminovitch K
    J Rheumatol; 1986 Jun; 13(3):483-5. PubMed ID: 3488400
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypersensitivity and infection in the pathogenesis of the rheumatic diseases.
    Walton KW
    Int Rev Exp Pathol; 1968; 6():285-374. PubMed ID: 4192074
    [No Abstract]   [Full Text] [Related]  

  • 4. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.
    Han B; Bojalil R; Amezcua-Guerra LM; Springall R; Valderrama-Carvajal H; Wu J; Luo H
    Int Immunol; 2008 Aug; 20(8):1067-75. PubMed ID: 18562337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobacco smoking and autoimmune rheumatic diseases.
    Harel-Meir M; Sherer Y; Shoenfeld Y
    Nat Clin Pract Rheumatol; 2007 Dec; 3(12):707-15. PubMed ID: 18037930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus: immunopathogenesis and the card game analogy.
    Isenberg DA
    J Rheumatol Suppl; 1997 May; 48():62-6. PubMed ID: 9150121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environment and systemic lupus erythematosus: an overview.
    Sarzi-Puttini P; Atzeni F; Iaccarino L; Doria A
    Autoimmunity; 2005 Nov; 38(7):465-72. PubMed ID: 16373251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of complement proteins in rheumatic disease.
    George D; Glass D
    Clin Rheum Dis; 1983 Apr; 9(1):177-98. PubMed ID: 6603322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifactorial etiology of rheumatic diseases.
    Barnett EV
    J Rheumatol; 1975 Jun; 2(2):125-9. PubMed ID: 1097681
    [No Abstract]   [Full Text] [Related]  

  • 10. Complement and its breakdown products in SLE.
    Sturfelt G; Truedsson L
    Rheumatology (Oxford); 2005 Oct; 44(10):1227-32. PubMed ID: 15972354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking as a trigger for inflammatory rheumatic diseases.
    Klareskog L; Padyukov L; Alfredsson L
    Curr Opin Rheumatol; 2007 Jan; 19(1):49-54. PubMed ID: 17143096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease.
    Schett G; Dumortier H; Hoefler E; Muller S; Steiner G
    Ann Rheum Dis; 2009 May; 68(5):729-35. PubMed ID: 18495733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunology of systemic lupus erythematosus and related rheumatic diseases.
    Koffler D
    Clin Symp; 1987; 39(2):2-36. PubMed ID: 3496187
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement deficiencies in humans and animals: links to autoimmunity.
    Lewis MJ; Botto M
    Autoimmunity; 2006 Aug; 39(5):367-78. PubMed ID: 16923536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune mechanisms in rheumatic disease.
    Workman ML
    Nurs Clin North Am; 2000 Mar; 35(1):175-88. PubMed ID: 10673573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
    Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
    Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental use of murine lupus models.
    Peng SL
    Methods Mol Med; 2004; 102():227-72. PubMed ID: 15286389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunopathologic mechanism in some ocular diseases].
    Rogoz S; Avramescu C; Siloşi I; Drackoulogona O; Badea P; State A
    Oftalmologia; 2002; 54(3):51-5. PubMed ID: 12723199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
    Singh V; Mahoney JA; Petri M
    J Rheumatol; 2008 Oct; 35(10):1989-93. PubMed ID: 18709693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.
    Illei GG; Tackey E; Lapteva L; Lipsky PE
    Arthritis Rheum; 2004 Jul; 50(7):2048-65. PubMed ID: 15248202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.